{"id":92047,"date":"2024-04-09T15:13:00","date_gmt":"2024-04-09T18:13:00","guid":{"rendered":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/releases\/releases-geral\/bright-peak-therapeutics-presents-new-data-at-the-2024-american-association-for-cancer-research-aacr-annual-meeting\/"},"modified":"2024-04-09T15:13:00","modified_gmt":"2024-04-09T18:13:00","slug":"bright-peak-therapeutics-presents-new-data-at-the-2024-american-association-for-cancer-research-aacr-annual-meeting","status":"publish","type":"post","link":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/releases\/releases-geral\/bright-peak-therapeutics-presents-new-data-at-the-2024-american-association-for-cancer-research-aacr-annual-meeting\/","title":{"rendered":"Bright Peak Therapeutics Presents New Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting"},"content":{"rendered":"<p><b>Bright Peak Therapeutics, Inc.<\/b><\/p>\n<p align=\"justify\">SAN DIEGO and BASEL, Switzerland, April  09, 2024  (GLOBE NEWSWIRE) &#8212; Bright Peak Therapeutics, a biotechnology company developing multifunctional immunotherapies for cancer and autoimmune disease, today announced the presentation of new data characterizing the mechanisms of action, and potent preclinical antitumor activity of BPT567, a cis-signaling, PD1-IL18 immunoconjugate, at the American Association for Cancer Research (AACR) Annual Meeting being held on April 4-10, 2024, in San Diego, CA.<\/p>\n<p align=\"justify\">Bright Peak has leveraged its world-class protein engineering capabilities to functionally optimize the master cytokine IL-18, by creating an IL-18 binding protein-resistant molecule and integrating it with PD-1 checkpoint blockade to create BPT567, a first-in-class PD1-IL18 immunoconjugate. Antibody-cytokine conjugates leverage orthogonal mechanisms of action (MoA) in one molecule to induce potent antitumor immune responses. PD-1-targeting conjugates are of particular interest since they may preferentially target antigen-experienced PD-1+ CD8+ T cells enriched in the tumor microenvironment (TME) while simultaneously blocking the PD-(L)1 pathway and inducing potent cytokine receptor stimulation in the same CD8+ T cell in cis (cis-signaling).<\/p>\n<p align=\"justify\">BPT567 is designed to coordinately engage antigen-experienced T<sub>eff<\/sub>\u00a0cells that are known to co-express both PD-1 and the IL-18 receptor. These T-cells have been reported to be highly cytotoxic and enriched in the tumor microenvironment, and as a PD1-IL18 immunoconjugate, BPT567 is designed uniquely to target these cells, said Jon Wigginton, M.D., President of Research and Development of Bright Peak Therapeutics.<\/p>\n<p align=\"justify\">Dr. Wigginton continued Characterization of the biological activity of BPT567 in preclinical tumor models has demonstrated that BPT567 indeed can more selectively target the potent proinflammatory effects of IL-18 to the tumor, with more limited activation of immune cells in the periphery. It is anticipated that this profile could ultimately contribute to an improved risk-benefit profile for BPT567 in the clinical setting.<\/p>\n<p><strong>Details regarding the AACR abstract presentations are as follows:<\/strong><\/p>\n<p><strong>April 09, 2024, 9:00 AM  12:30 PM (PDT)<\/strong><\/p>\n<p><strong>Poster 4071: The first-in-class PD1-IL18 conjugate BPT567 induces potent anti-tumor immunity by preferentially activating PD1+IL18R+ intratumoral effector T cells <\/strong><strong><em>in cis<\/em><\/strong><\/p>\n<p align=\"justify\">The poster will be made available for viewing on Bright Peaks website upon presentation at the AACR 2024 Annual Meeting (www.brightpeaktx.com).<\/p>\n<p><strong>Key Abstract Highlights: <\/strong><\/p>\n<ul type=\"disc\">\n<li style=\"text-align:justify\"><em>BPT567 is designed to preferentially target antigen-experienced PD-1+ CD8+ T cells found to be enriched in the tumor microenvironment<\/em><\/li>\n<li style=\"text-align:justify\"><em>BPT567 provides simultaneous blockade of the PD-(L)1 pathway and potent induction of IL-18 receptor stimulation in the same CD8+ T cell in cis (cis-signaling)<\/em><\/li>\n<li style=\"text-align:justify\"><em>Engagement of a low number of PD-1 and IL-18 receptors by BPT567 is fully sufficient to induce maximum IFN<\/em><em>g<\/em><em> release in PD-1+ cells<\/em><\/li>\n<li style=\"text-align:justify\"><em>BPT567 exhibits strong anti-tumor efficacy at significantly lower relative IL-18 doses compared to the administration of an untargeted Ab-IL-18 conjugate and an anti-PD-1 Ab given in combination<\/em><\/li>\n<\/ul>\n<p><strong>About Bright Peak Therapeutics\u00a0<\/strong><br \/>Bright Peak Therapeutics is a biotechnology company advancing a portfolio of multifunctional immunotherapies for the treatment of patients with cancer and autoimmune disease. We accomplish this by leveraging our world class protein engineering capabilities and our unique cell-free technology platform to chemically synthesize and conjugate novel protein therapeutics that reflect state-of-the-art insights into cytokine and immune checkpoint biology. Our pipeline stretches from discovery to IND-enabling and encompasses antibody-cytokine conjugates and other novel formats. Bright Peak is based in Basel, Switzerland and Del Mar, CA and is funded by a syndicate of leading healthcare investors.<br \/>Contact:\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=7nqgWm6fqkkNdFdNgO1H7T5kinY49rUeTsYfiEbn-l0gc2207G3j_jKfuwfoGrAqykThousn-yIONY4EzzCDAYa94vEKjwWpZ8grbVlN1yU=\" rel=\"nofollow noopener\" target=\"_blank\"><u>info@brightpeaktx.com<\/u><\/a><\/p>\n<p \/> <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTA4NzAxMiM2MTk0MjEzIzIyMDg1OTI=\" \/> <br \/><img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/YmNlODcwMjAtZTUzNC00NmI5LWIxMTYtYTY1MzcyMWVmNDliLTEyMjAxNDU=\/tiny\/Bright-Peak-Therapeutics-Inc-.png\" \/><br \/>\n<a href=\"https:\/\/www.globenewswire.com\/NewsRoom\/AttachmentNg\/defa8f89-29e0-4a90-9f7b-9a417c34ce26\"><img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/defa8f89-29e0-4a90-9f7b-9a417c34ce26\/small\/bright-peak-tx-logo-center-rgb-small-png.png\" border=\"0\" width=\"150\" height=\"130\" alt=\"Primary Logo\" \/><\/a><\/p>\n<p>A <b>OESP<\/b> nao e(sao) responsavel(is) por erros, incorrecoes, atrasos ou quaisquer decisoes tomadas por seus clientes com base nos Conteudos ora disponibilizados, bem como tais Conteudos nao representam a opiniao da <b>OESP<\/b> e sao de inteira responsabilidade da <b>GlobeNewswire<\/b><\/p>\n","protected":false},"excerpt":{"rendered":"SAN DIEGO and BASEL, Switzerland, April  09, 2024  (GLOBE NEWSWIRE) &#8212; Bright Peak Therapeutics, a biotechnology company developing multifunctional immuno","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[34],"tags":[],"class_list":["post-92047","post","type-post","status-publish","format-standard","hentry","category-releases-geral"],"acf":[],"_links":{"self":[{"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/posts\/92047","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/comments?post=92047"}],"version-history":[{"count":0,"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/posts\/92047\/revisions"}],"wp:attachment":[{"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/media?parent=92047"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/categories?post=92047"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/tags?post=92047"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}